On April 24, 2024 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, reported that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL (Press release, Cue Biopharma, APR 24, 2024, View Source [SID1234642302]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-based biologics, CUE-101 in recurrent/metastatic head and neck cancer and CUE-102 in Wilms’ Tumor 1 positive recurrent/metastatic cancers.
The Company will host a Business Update call and webcast in June 2024 that will include a discussion on the clinical progress and associated data presented at ASCO (Free ASCO Whitepaper) on June 1 and June 4. Call details will be issued prior to the event.
Oral Abstract and Poster Details
Abstract Number: 6004
Title: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
Presenter: Douglas R. Atkins, M.D., Professor of Medicine, Washington University School of Medicine
Session Type and Title: Oral Abstract Session; Head and Neck Cancer
Session Date and Time: June 4, 2024, 9:45 AM-12:45 PM CDT
Abstract Number: 3553
Title: A phase 1 open-label, dose escalation and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201 positive disease and WT1-positive recurrent/metastatic cancers.
Presenter: Nataliya Uboha, M.D., Ph.D. University of Wisconsin Carbone Cancer Center
Session Type and Title: Poster Session; Gastrointestinal Cancer, Colorectal and Anal
Session Date and Time: June 1, 2024, 1:30 PM-4:30 PM CDT
The oral abstract and poster presentations will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under Scientific Publications and Presentations, following ASCO (Free ASCO Whitepaper).